Overview

* Pfizer ( PFE ) Q3 revenue of $16.65 bln beats analyst expectations despite a 6% yr/yr decline

* Adjusted EPS for Q3 beats consensus, with strong operational performance

* Company raises full-year 2025 adjusted EPS guidance, reflecting confidence in business

Outlook

* Pfizer ( PFE ) reaffirms full-year 2025 revenue guidance of $61.0 to $64.0 bln

* Raises and narrows full-year 2025 adjusted EPS guidance to $3.00-$3.15

* Guidance includes impact of tariffs from China, Canada, and Mexico

Result Drivers

* COVID-19 PRODUCT DECLINE - Lower infection rates and reduced vaccine recommendations in the U.S. led to decreased COVID-19 product revenues

* NON-COVID GROWTH - Strong demand for Eliquis, Vyndaqel, and Nurtec ODT/Vydura drove growth in non-COVID portfolio

* COST IMPROVEMENT - On track to deliver $7.2 bln in anticipated net cost savings by end of 2027, aiding productivity and margin expansion

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $16.65 $16.57

Revenue bln bln (14

Analysts

)

Q3 Beat $0.87 $0.62

Adjusted (14

EPS Analysts

)

Q3 EPS $0.62

Q3 Net $3.54

Income bln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Pfizer Inc ( PFE ) is $29.00, about 15% above its November 3 closing price of $24.66

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)